# Early phase 1 pancreatic cancer trials recruiting: 24 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials in early phase 1 for pancreatic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Early phase 1 pancreatic cancer trials: 24 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/early-phase-1/pancreatic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 24
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 24, 2026 | NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | Lumina Pharmaceuticals Inc | Early phase 1 | Not yet recruiting | Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC)... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781852) |
| July 16, 2026 | NCT07707531 | A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and... | Huashan Hospital | Early phase 1 | Recruiting | Gastric Cancer, Pancreatic Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07707531) |
| June 16, 2026 | NCT07649928 | A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer | Ruijin Hospital | Early phase 1 | Recruiting | Pancreatic Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649928) |
| June 10, 2026 | NCT07639970 | Evaluation of \[⁶⁸Ga/¹⁷⁷Lu\]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors | Sponsor not shown (see the record) | Early phase 1 | Not yet recruiting | Breast Cancer, Head and Neck Cancer (H&N), Pancreatic Cancer, Glioma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07639970) |
| June 4, 2026 | NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | University of Arizona | Early phase 1 | Recruiting | Pancreatic Cancer, Colorectal Cancer, Hepatocellular Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627191) |
| May 19, 2026 | NCT07597772 | Preliminary Trial of SNA014 for Pancreatic Cancer | SmartNuclide Biopharma | Early phase 1 | Recruiting | Pancreatic Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07597772) |
| February 6, 2026 | NCT07394205 | Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer | First Affiliated Hospital of Wenzhou Medical University | Early phase 1 | Not yet recruiting | Advanced Gastric and Pancreatic Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07394205) |
| November 28, 2025 | NCT07254091 | Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer | Northwell Health | Early phase 1 | Recruiting | Pancreatic Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254091) |
| November 19, 2025 | NCT07236177 | B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the... | Poitiers University Hospital | Early phase 1 | Recruiting | Breast Cancer, Pancreatic Cancer, Pulmonary Cancer, Volatile Organic Compound, Glycosidase Activity, Probes, Tumor... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07236177) |
| July 29, 2025 | NCT07089940 | OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | OHSU Knight Cancer Institute | Early phase 1 | Recruiting | Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07089940) |
| June 24, 2025 | NCT07033689 | Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II) | SONIRE Therapeutics Inc. | Early phase 1 | Recruiting | Pancreatic Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07033689) |
| June 18, 2025 | NCT07026981 | \[Ga-68\]MTP220 PET for Biodistribution and Efficacy in Pancreatic Cancer and Head and Neck Cancers | Sponsor not shown (see the record) | Early phase 1 | Not yet recruiting | Head and Neck Cancer, Pancreatic Cancer, Cancer Pancreas | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07026981) |
| February 14, 2025 | NCT06828328 | A Study of GC203 TIL in PDCA (RJ) | Shanghai Juncell Therapeutics | Early phase 1 | Recruiting | Pancreatic Cancer, Pancratic Ductal Adenocarcinoma, Treatment Side Effects, Tumor Infiltrating Lymphocytes | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06828328) |
| October 17, 2024 | NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors | Var2 Pharmaceuticals | Early phase 1 | Recruiting | Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma, Chondrosarcoma, Lung Carcinoma, Head and Neck Squamous... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06645808) |
| October 16, 2024 | NCT06645301 | BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies | BioSyngen Pte Ltd | Early phase 1 | Not yet recruiting | Colorectal Cancer, Pancreatic Cancer | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06645301) |
| October 1, 2024 | NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Early phase 1 | Not yet recruiting | Solid Tumor, Adult, Lung Adenocarcinoma, Pancreas Cancer, Colorectal Cancer, Other Solid Tumor | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06619886) |
| August 29, 2024 | NCT06577532 | Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors | Ruijin Hospital | Early phase 1 | Recruiting | Pancreatic Neoplasms, Other Solid Tumors | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06577532) |
| July 11, 2024 | NCT06496373 | Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer | Ruijin Hospital | Early phase 1 | Recruiting | Pancreatic Cancer Resectable, Chemotherapy-intolerant | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06496373) |
| March 22, 2024 | NCT06326736 | Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer | Jinling Hospital, China | Early phase 1 | Recruiting | Pancreatic Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06326736) |
| January 9, 2024 | NCT06196658 | Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer | Sponsor not shown (see the record) | Early phase 1 | Not yet recruiting | Pancreatic Cancer, Advanced Biliary Cancer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06196658) |
| December 5, 2023 | NCT06156267 | Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino | Fudan University | Early phase 1 | Not yet recruiting | Pancreatic Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06156267) |
| November 8, 2023 | NCT06122896 | Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals | Dana-Farber Cancer Institute | Early phase 1 | Recruiting | Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasm | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06122896) |
| August 7, 2019 | NCT04048278 | Lidocaine Infusion in Pancreatic Cancer | University of Illinois Chicago | Early phase 1 | Recruiting | Pancreatic Cancer | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04048278) |
| July 2, 2019 | NCT04005690 | Targeted Pathway Inhibition in Patients With Pancreatic Cancer | OHSU Knight Cancer Institute | Early phase 1 | Recruiting | Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04005690) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Ruijin Hospital | 3 |
| OHSU Knight Cancer Institute | 2 |
| SONIRE Therapeutics Inc. | 1 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| Var2 Pharmaceuticals | 1 |
| Dana-Farber Cancer Institute | 1 |
| BioSyngen Pte Ltd | 1 |
| University of Illinois Chicago | 1 |
| Poitiers University Hospital | 1 |
| SmartNuclide Biopharma | 1 |
| Shanghai Juncell Therapeutics | 1 |
| Huashan Hospital | 1 |
| Northwell Health | 1 |
| Jinling Hospital, China | 1 |
| Lumina Pharmaceuticals Inc | 1 |
| Fudan University | 1 |
| First Affiliated Hospital of Wenzhou Medical University | 1 |
| University of Arizona | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 10 |
| United States | 9 |
| Netherlands | 1 |
| France | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Private equity firms in the United States](https://specstream.ai/data/businesses/private-equity-firms/united-states)
- [Doner kebab restaurants in the United States](https://specstream.ai/data/businesses/doner-kebab-restaurants/united-states)
- [Solar installers in the United States](https://specstream.ai/data/businesses/solar-installers/united-states)
- [Food and beverage consultants in the United States](https://specstream.ai/data/businesses/food-and-beverage-consultants/united-states)
- [Vascular medicine practices in the United States](https://specstream.ai/data/businesses/vascular-medicine-practices/united-states)
- [Indian restaurants in the United States](https://specstream.ai/data/businesses/indian-restaurants/united-states)
